Ligand Pharmaceuticals Incorporated (LGND)Stock Price & Financial Statements
AboutLigand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.Show more
- Revenue $167M +27.3%
- EBITDA $13M -73.9%
- Net Income -$4M -107.7%
- EPS (Diluted) -0.22 -107.5%
- Gross Margin 93.37% +27.4%
- EBITDA Margin 7.56% -79.5%
- Operating Margin -13.53% -248.7%
- Net Margin -2.41% -106.1%
- ROE -0.53% -106.6%
- ROIC -2.34% -273.0%
- Debt/Equity 0.01 -2.7%
- Interest Coverage -7.44 -140.9%
Key Insights
Based on financial data analysisStrengths
- ✓Company is almost debt free
- ✓FCF machine: 46.3% free cash flow margin
- ✓Momentum leader: RS Rating 81 (top 19%)
- ✓Trading near 52-week high
Weaknesses
- ✗Weak 3Y average ROE of 0.9%
- ✗Low asset turnover indicates capital-intensive operations
Price & Volume
Loading chart...
Growth Metrics
Revenue CAGR
10Y9.98%
5Y6.8%
3Y-11.55%
TTM64.83%
Profit (Net Income) CAGR
10Y-
5Y-
3Y-
TTM7.38%
EPS CAGR
10Y-
5Y-
3Y-
TTM-17.53%
ROCE
10Y Avg12.54%
5Y Avg2.05%
3Y Avg-0.24%
Latest-2.7%
Peer Comparison
Royalty and IP Monetization Vehicles| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
 BTXBlackRock Technology and Private Equity Term Trust | 772.62M | 6.62 | 38.94 | -81.13% | 87.75% | 1.87% | 35.88% | |
 RPRXRoyalty Pharma plc | 26.77B | 47.43 | 26.65 | 5.06% | 32.55% | 7.95% | 9.3% | 0.91 |
 INVAInnoviva, Inc. | 1.7B | 22.73 | 6.89 | 18.52% | 65.38% | 23.12% | 11.54% | |
 CDTCDT Equity Inc. | 1.46M | 0.71 | -0.03 | -474.64% | ||||
 CBUSCibus, Inc. | 98.77M | 3.33 | -0.31 | 134.56% | -31.34% | -228.53% | 0.37 | |
 XOMAPXOMA Corporation | 317.24M | 25.77 | -15.62 | 498.72% | 46.15% | 20.14% | 1.46 | |
 XOMAXOMA Royalty Corp. | 316.14M | 26.45 | -16.03 | 498.72% | 41.06% | 17.91% | 1.46 | |
LGNDLigand Pharmaceuticals Incorporated | 4.11B | 208.95 | -949.77 | 27.28% | 19.34% | 5.11% | 1.88% | 0.01 |
Compare LGND vs Peers
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
Income Statement
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 71.91M | 108.97M | 141.1M | 251.45M | 120.28M | 163.56M | 241.54M | 196.25M | 131.31M | 167.13M |
| Revenue Growth % | 11.43% | 51.53% | 29.48% | 78.21% | -52.17% | 35.98% | 47.68% | -18.75% | -33.09% | 27.28% |
| Cost of Goods Sold | 5.81M | 5.57M | 5.37M | 6.34M | 11.35M | 30.42M | 62.18M | 52.83M | 35.05M | 11.07M |
| COGS % of Revenue | 8.07% | 5.11% | 3.8% | 2.52% | 9.43% | 18.6% | 25.74% | 26.92% | 26.69% | 6.63% |
| Gross Profit | 66.11M | 103.4M | 135.74M | 245.12M | 108.94M | 133.14M | 179.37M | 143.42M | 96.27M | 156.06M |
| Gross Margin % | 91.93% | 94.89% | 96.2% | 97.48% | 90.57% | 81.4% | 74.26% | 73.08% | 73.31% | 93.37% |
| Gross Profit Growth % | 19.32% | 56.42% | 31.27% | 80.58% | -55.56% | 22.22% | 34.72% | -20.04% | -32.88% | 62.11% |
| Operating Expenses | 37.76M | 58.48M | 67.66M | 81.39M | -698.14M | 95.64M | 75.52M | 140.38M | 84.32M | 178.66M |
| OpEx % of Revenue | 52.5% | 53.67% | 47.95% | 32.37% | -580.42% | 58.48% | 31.26% | 71.53% | 64.21% | 106.9% |
| Selling, General & Admin | 24.38M | 26.62M | 28.65M | 37.73M | 41.88M | 60.01M | 46.79M | 70.06M | 52.79M | 78.65M |
| SG&A % of Revenue | 33.9% | 24.43% | 20.31% | 15.01% | 34.82% | 36.69% | 19.37% | 35.7% | 40.2% | 47.06% |
| Research & Development | 13.38M | 21.22M | 26.89M | 27.86M | 55.91M | 40.5M | 32.1M | 36.08M | 24.54M | 21.43M |
| R&D % of Revenue | 18.61% | 19.47% | 19.05% | 11.08% | 46.48% | 24.76% | 13.29% | 18.39% | 18.69% | 12.82% |
| Other Operating Expenses | 0 | 10.64M | 12.12M | 15.79M | -795.93M | -4.87M | -3.38M | 34.24M | 7M | 78.59M |
| Operating Income | 27.33M | 43.88M | 68.08M | 163.73M | 807.08M | 37.5M | 103.85M | 3.04M | 11.94M | -22.61M |
| Operating Margin % | 38% | 40.27% | 48.25% | 65.11% | 670.99% | 22.93% | 42.99% | 1.55% | 9.09% | -13.53% |
| Operating Income Growth % | 39.25% | 60.58% | 55.12% | 140.51% | 392.94% | -95.35% | 176.94% | -97.08% | 293.22% | -289.3% |
| EBITDA | 29.96M | 55.17M | 80.6M | 180.42M | 850.81M | 65.47M | 154.8M | 46.43M | 48.46M | 12.63M |
| EBITDA Margin % | 41.66% | 50.63% | 57.12% | 71.75% | 707.34% | 40.03% | 64.09% | 23.66% | 36.91% | 7.56% |
| EBITDA Growth % | 34.43% | 84.19% | 46.07% | 123.86% | 371.57% | -92.31% | 136.45% | -70.01% | 4.38% | -73.93% |
| D&A (Non-Cash Add-back) | 2.63M | 11.29M | 12.52M | 16.69M | 43.73M | 27.97M | 50.95M | 43.39M | 36.52M | 35.24M |
| EBIT | 27.33M | 20.8M | 68.63M | 221.61M | 832.38M | 28.71M | 91.82M | 37.81M | 64.32M | 5.55M |
| Net Interest Income | -11.8M | -12.18M | -11.4M | -34.28M | -7.32M | -19.34M | -18.73M | 247K | 7.05M | 5.02M |
| Interest Income | 0 | 0 | 0 | 14M | 28.43M | 8.08M | 886K | 2.05M | 7.71M | 8.05M |
| Interest Expense | 11.8M | 12.18M | 11.4M | 48.28M | 35.74M | 27.41M | 19.62M | 1.8M | 656K | 3.04M |
| Other Income/Expense | 8M | -35.92M | -10.85M | 9.6M | -10.44M | -36.21M | -31.65M | 32.97M | 51.72M | 25.12M |
| Pretax Income | 35.33M | 7.96M | 57.23M | 173.33M | 796.64M | 1.29M | 72.2M | 36.01M | 63.66M | 2.52M |
| Pretax Margin % | 49.13% | 7.3% | 40.56% | 68.93% | 662.31% | 0.79% | 29.89% | 18.35% | 48.48% | 1.51% |
| Income Tax | -219.6M | 10.33M | 44.67M | 30.01M | 167.34M | -5.31M | -4.15M | 41.23M | 9.84M | 6.55M |
| Effective Tax Rate % | 728.31% | -20.55% | 21.94% | 82.69% | 78.99% | -231.04% | 79.13% | -92.64% | 81.93% | -160.13% |
| Net Income | 257.31M | -1.64M | 12.56M | 143.32M | 629.3M | -2.98M | 57.14M | -33.36M | 52.15M | -4.03M |
| Net Margin % | 357.8% | -1.5% | 8.9% | 57% | 523.19% | -1.82% | 23.66% | -17% | 39.72% | -2.41% |
| Net Income Growth % | 2039.93% | -100.64% | 867.48% | 1041.45% | 339.09% | -100.47% | 2014.17% | -158.39% | 256.33% | -107.73% |
| Net Income (Continuing) | 227.44M | -2.37M | 12.56M | 143.32M | 629.3M | 6.6M | 76.35M | -5.22M | 53.82M | -4.03M |
| Discontinued Operations | 0 | 731K | 0 | 0 | 0 | -9.58M | -19.21M | -28.14M | -1.67M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 12.12 | -0.08 | 0.53 | 5.96 | 31.85 | -0.18 | 3.34 | -1.98 | 2.94 | -0.22 |
| EPS Growth % | 2064.29% | -100.65% | 775.16% | 1024.53% | 434.4% | -100.57% | 1955.56% | -159.28% | 248.48% | -107.48% |
| EPS (Basic) | 13.00 | -0.08 | 0.60 | 5.96 | 33.13 | -0.18 | 3.46 | -1.98 | 3.02 | -0.22 |
| Diluted Shares Outstanding | 21.23M | 20.83M | 23.48M | 24.07M | 19.76M | 16.18M | 17.25M | 16.87M | 17.76M | 18.29M |
| Basic Shares Outstanding | 19.79M | 20.83M | 21.03M | 24.05M | 19M | 16.18M | 16.63M | 16.87M | 17.3M | 18.29M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 215.57M | 163.05M | 237.02M | 870.54M | 1.12B | 500.56M | 464.75M | 263.6M | 237.43M | 331.56M |
| Cash & Short-Term Investments | 200.22M | 141.05M | 201.66M | 764.57M | 1.07B | 411.19M | 341.11M | 211.87M | 170.31M | 256.17M |
| Cash Only | 200.22M | 141.05M | 201.66M | 718.38M | 71.54M | 47.62M | 19.52M | 45.01M | 22.95M | 72.31M |
| Short-Term Investments | 0 | 0 | 0 | 46.19M | 998.32M | 363.57M | 321.59M | 166.86M | 147.35M | 183.86M |
| Accounts Receivable | 11.68M | 18.22M | 25.6M | 55.85M | 41.75M | 59.06M | 91.65M | 35.04M | 39.31M | 42.45M |
| Days Sales Outstanding | 59.3 | 61.02 | 66.21 | 81.07 | 126.69 | 131.81 | 138.49 | 65.17 | 109.27 | 92.7 |
| Inventory | 1.63M | 1.92M | 4.37M | 7.12M | 7.3M | 26.49M | 27.33M | 13.29M | 23.97M | 14.11M |
| Days Inventory Outstanding | 102.64 | 125.99 | 297.46 | 410.33 | 234.69 | 317.82 | 160.42 | 91.85 | 249.61 | 465.2 |
| Other Current Assets | 0 | 0 | 5.39M | 89.19M | 4.73M | 3.82M | 4.67M | 2.27M | 2.66M | 16.9M |
| Total Non-Current Assets | 318.36M | 438.53M | 434M | 390.26M | 371.27M | 861.73M | 832.84M | 499.07M | 549.79M | 610.22M |
| Property, Plant & Equipment | 372K | 1.82M | 4.21M | 5.37M | 17.62M | 37.17M | 32.6M | 27.49M | 25.06M | 24.81M |
| Fixed Asset Turnover | 193.32x | 59.91x | 33.50x | 46.81x | 6.83x | 4.40x | 7.41x | 7.14x | 5.24x | 6.74x |
| Goodwill | 60.59M | 276.91M | 314.54M | 306.44M | 95.23M | 189.66M | 105.67M | 105.67M | 103.37M | 105.25M |
| Intangible Assets | 8.55M | 25.82M | 19.53M | 31.46M | 230.54M | 606.31M | 386.8M | 352.64M | 299.61M | 266.65M |
| Long-Term Investments | 29.73M | 8.35M | 6.44M | 601.22M | 0 | 0 | 0 | 3M | 111.61M | 10.91M |
| Other Non-Current Assets | 2.55M | 1.74M | 4.86M | -600.75M | 2.27M | 4.27M | 272.03M | 1.74M | 9.92M | 202.53M |
| Total Assets | 533.93M | 601.59M | 671.02M | 1.26B | 1.49B | 1.36B | 1.3B | 762.67M | 787.22M | 941.77M |
| Asset Turnover | 0.13x | 0.18x | 0.21x | 0.20x | 0.08x | 0.12x | 0.19x | 0.26x | 0.17x | 0.18x |
| Asset Growth % | 106.93% | 12.67% | 11.54% | 87.89% | 18.57% | -8.87% | -4.75% | -41.22% | 3.22% | 19.63% |
| Total Current Liabilities | 20.84M | 227.13M | 238.87M | 82.25M | 17M | 100.11M | 41.66M | 98.81M | 16.78M | 37.11M |
| Accounts Payable | 4.08M | 2.73M | 2.26M | 4.18M | 2.42M | 3.78M | 8.4M | 5.31M | 2.43M | 5.23M |
| Days Payables Outstanding | 256.64 | 179.13 | 153.66 | 240.93 | 77.84 | 45.4 | 49.33 | 36.67 | 25.27 | 172.48 |
| Short-Term Debt | 201.99M | 212.91M | 224.53M | 26.43M | 0 | 0 | 0 | 76.69M | 0 | 0 |
| Deferred Revenue (Current) | -934K | 0 | 173K | 3.29M | 2.14M | 29.43M | 654K | 976K | 1.84M | 1.9M |
| Other Current Liabilities | 15.04M | 5.09M | 1.41M | 44.3M | 7.62M | 49.38M | 22.57M | 6.26M | 4.94M | -3.2M |
| Current Ratio | 10.35x | 0.72x | 0.99x | 10.58x | 66.09x | 5.00x | 11.15x | 2.67x | 14.15x | 8.93x |
| Quick Ratio | 10.27x | 0.71x | 0.97x | 10.50x | 65.66x | 4.74x | 10.50x | 2.53x | 12.72x | 8.55x |
| Cash Conversion Cycle | -94.7 | 7.89 | 210.01 | 250.47 | 283.53 | 404.22 | 249.57 | 120.35 | 333.61 | 385.42 |
| Total Non-Current Liabilities | 208.7M | 3.6M | 13.51M | 617.64M | 710.68M | 552.65M | 434.77M | 66.37M | 69.52M | 74.22M |
| Long-Term Debt | 205.37M | 29.56M | 18.86M | 609.86M | 638.96M | 442.29M | 320.72M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 9.97M | 5.64M | 2.26M | 10.34M | 5.75M | 5.82M |
| Deferred Tax Liabilities | 0 | -357K | -22.38M | 51.97M | 32.94M | 64.6M | 30.86M | 30.61M | 31.62M | 32.52M |
| Other Non-Current Liabilities | 3.33M | -25.96M | -8.88M | 7.78M | 28.82M | 40.12M | 80.94M | 25.38M | 17M | 35.88M |
| Total Liabilities | 229.54M | 230.73M | 252.37M | 699.89M | 727.68M | 652.76M | 476.43M | 165.18M | 86.3M | 111.33M |
| Total Debt | 205.37M | 212.91M | 224.53M | 636.3M | 650.18M | 456.41M | 324.39M | 87.75M | 6.17M | 7.11M |
| Net Debt | 5.15M | 71.86M | 22.87M | -82.08M | 578.64M | 408.8M | 304.86M | 42.74M | -16.79M | -65.2M |
| Debt / Equity | 0.67x | 0.57x | 0.54x | 1.13x | 0.85x | 0.64x | 0.40x | 0.15x | 0.01x | 0.01x |
| Debt / EBITDA | 6.86x | 3.86x | 2.79x | 3.53x | 0.76x | 6.97x | 2.10x | 1.89x | 0.13x | 0.56x |
| Net Debt / EBITDA | 0.17x | 1.30x | 0.28x | -0.45x | 0.68x | 6.24x | 1.97x | 0.92x | -0.35x | -5.16x |
| Interest Coverage | 2.32x | 3.60x | 5.97x | 3.39x | 22.58x | 1.37x | 5.29x | 1.69x | 18.20x | -7.44x |
| Total Equity | 304.39M | 370.85M | 418.65M | 560.91M | 767.23M | 709.52M | 821.16M | 597.49M | 700.91M | 830.44M |
| Equity Growth % | 1147.1% | 21.83% | 12.89% | 33.98% | 36.78% | -7.52% | 15.73% | -27.24% | 17.31% | 18.48% |
| Book Value per Share | 14.34 | 17.80 | 17.83 | 23.31 | 38.83 | 43.84 | 47.61 | 35.42 | 39.47 | 45.40 |
| Total Shareholders' Equity | 304.39M | 370.85M | 418.65M | 560.91M | 767.23M | 709.52M | 821.16M | 597.49M | 700.91M | 830.44M |
| Common Stock | 20K | 21K | 21K | 21K | 17K | 16K | 17K | 17K | 18K | 20K |
| Retained Earnings | -402.01M | -431.13M | -400.92M | -229.2M | 400.11M | 391.95M | 449.09M | 450.86M | 503.02M | 498.98M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4.9M | 2.74M | 2.49M | -1.02M | -216K | -801K | -917K | -984K | -817K | -5.94M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash Flow Statement
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 41.73M | 63M | 93.57M | 194.06M | -29.34M | 54.59M | 78.8M | 137.85M | 49.58M | 97.05M |
| Operating CF Margin % | 58.02% | 57.81% | 66.31% | 77.18% | -24.39% | 33.37% | 32.62% | 70.24% | 37.75% | 58.07% |
| Operating CF Growth % | 102.89% | 50.98% | 48.52% | 107.4% | -115.12% | 286.07% | 44.36% | 74.94% | -64.04% | 95.75% |
| Net Income | 254.93M | -2.37M | 12.56M | 143.32M | 629.3M | -2.98M | 57.14M | -33.36M | 52.15M | -4.03M |
| Depreciation & Amortization | 2.63M | 11.29M | 11.71M | 14.72M | 43.73M | 27.97M | 50.95M | 51.37M | 36.52M | 35.24M |
| Stock-Based Compensation | 12.46M | 18.89M | 24.91M | 20.85M | 24.52M | 30.73M | 38.78M | 60.28M | 25.74M | 41.09M |
| Deferred Taxes | -219.61M | 10.7M | 44.52M | 29.74M | 74.83M | -19.05M | -8.62M | 20.72M | 11.7M | -15.8M |
| Other Non-Cash Items | -9.49M | 35.11M | 11.3M | 24.29M | -797.5M | 28M | -7.29M | -26.84M | -42.13M | 21.2M |
| Working Capital Changes | 821K | -10.62M | -11.44M | -38.85M | -4.21M | -10.06M | -52.16M | 65.68M | -34.4M | 19.36M |
| Change in Receivables | 6.49M | -8.53M | -8.36M | -29.54M | 25.46M | -26.06M | -28.62M | 55.32M | -2.6M | -6.46M |
| Change in Inventory | -401K | -244K | -843K | -2.56M | -2.06M | -17.8M | -427K | 12.06M | -10.87M | 9.62M |
| Change in Payables | -4.03M | -2.37M | -1.71M | -4.54M | -18.05M | -1.25M | -1.17M | -3.34M | -4.7M | 0 |
| Cash from Investing | -112.86M | -143.19M | -84.18M | -423.27M | 466.92M | 231.65M | 30.52M | 163.62M | -11.68M | -143.66M |
| Capital Expenditures | -10.86M | -28.32M | -7.15M | -11.89M | -2.55M | -4.46M | -8.76M | -17.92M | -3.52M | -1.82M |
| CapEx % of Revenue | 15.11% | 25.99% | 5.07% | 4.73% | 2.12% | 2.73% | 3.63% | 9.13% | 2.68% | 1.09% |
| Acquisitions | -9.25M | -94.2M | -26.65M | -5.86M | -12.84M | -383.32M | 494K | -750K | -25.65M | -172.19M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -15.99M | 300K | 7.25M | 3.91M | 808.13M | 3.26M | -1.22M | -868K | -49.91M | -12.89M |
| Cash from Financing | 8.36M | 1.51M | -7.52M | 328.58M | -485.17M | -310.55M | -137.76M | -275.99M | -59.95M | 97.14M |
| Debt Issued (Net) | 0 | 0 | 0 | 532.33M | -27.32M | -231.76M | -146.01M | -261M | -76.9M | -25K |
| Equity Issued (Net) | -489K | 1000K | -1000K | -1000K | -1000K | -1000K | 1000K | -1000K | 0 | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -489K | -3.9M | -1.97M | -122.87M | -453.05M | -78M | -18.45M | -8.24M | 0 | 0 |
| Other Financing | 8.85M | -999K | -5.56M | -77.11M | -383K | -789K | -7.07M | -6.75M | 16.95M | 60.03M |
| Net Change in Cash | -62.77M | -78.68M | 1.87M | 99.16M | -47.51M | -24.31M | -28.44M | 25.48M | -22.05M | 49.35M |
| Free Cash Flow | 30.86M | 34.68M | 86.41M | 182.17M | -31.89M | 50.13M | 70.04M | 119.93M | -4.27M | 77.41M |
| FCF Margin % | 42.92% | 31.82% | 61.24% | 72.45% | -26.51% | 30.65% | 29% | 61.11% | -3.25% | 46.31% |
| FCF Growth % | 92.1% | 12.36% | 149.18% | 110.81% | -117.5% | 257.2% | 39.72% | 71.23% | -103.56% | 1911.96% |
| FCF per Share | 1.45 | 1.66 | 3.68 | 7.57 | -1.61 | 3.10 | 4.06 | 7.11 | -0.24 | 4.23 |
| FCF Conversion (FCF/Net Income) | 0.16x | -38.51x | 7.45x | 1.35x | -0.05x | -18.29x | 1.38x | -4.13x | 0.95x | -24.07x |
| Interest Paid | 1.82M | 1.84M | 1.84M | 1.51M | 5.83M | 4.46M | 3.03M | 1.43M | 288K | 263K |
| Taxes Paid | 28K | 38K | 157K | 341K | 103.82M | 2.13M | 3.72M | 11.64M | 8.77M | 19.21M |
Key Ratios
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 156.51% | -0.48% | 3.18% | 29.26% | 94.76% | -0.4% | 7.47% | -4.7% | 8.03% | -0.53% |
| Return on Invested Capital (ROIC) | 11.3% | 8.75% | 11.55% | 26.68% | 66.35% | 2.28% | 6.94% | 0.26% | 1.35% | -2.34% |
| Gross Margin | 91.93% | 94.89% | 96.2% | 97.48% | 90.57% | 81.4% | 74.26% | 73.08% | 73.31% | 93.37% |
| Net Margin | 357.8% | -1.5% | 8.9% | 57% | 523.19% | -1.82% | 23.66% | -17% | 39.72% | -2.41% |
| Debt / Equity | 0.67x | 0.57x | 0.54x | 1.13x | 0.85x | 0.64x | 0.40x | 0.15x | 0.01x | 0.01x |
| Interest Coverage | 2.32x | 3.60x | 5.97x | 3.39x | 22.58x | 1.37x | 5.29x | 1.69x | 18.20x | -7.44x |
| FCF Conversion | 0.16x | -38.51x | 7.45x | 1.35x | -0.05x | -18.29x | 1.38x | -4.13x | 0.95x | -24.07x |
| Revenue Growth | 11.43% | 51.53% | 29.48% | 78.21% | -52.17% | 35.98% | 47.68% | -18.75% | -33.09% | 27.28% |
Deep Dive Analysis
Explore detailed financial history, valuation models, and returns analysis
Valuation Overview
DCF models, peer multiples & analyst estimates
Total Return Calculator
Historical returns with dividends reinvested
Dividend History
Yield, growth, payout safety & DRIP calculator
Earnings History
EPS trends, net income & profitability analysis
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of valuation, profitability & efficiency metrics